VCIM
NRIX icon

Velan Capital Investment Management’s Nurix Therapeutics NRIX Stock Holding History

Velan Capital Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Hold
16,000
– – 0.16% 33
2025
Q4 		$304K Hold
16,000
– – 0.18% 32
2025
Q3 		$148K Buy
16,000
+6,000
+60% +$62.3K 0.14% 35
2025
Q2 		$114K Buy
+10,000
New +$108K 0.11% 31
2025
Q1 		– Sell
-97,889
Closed -$1.84M – 55
2024
Q4 		$1.84M Buy
+97,889
New +$2.24M 1.59% 13

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Velan Capital Investment Management's NRIX Position: Q1 2026 in Review

Velan Capital Investment Management held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 16,000 shares worth $248K. The position accounts for 0.16% of the portfolio, ranked #33.

Velan Capital Investment Management first reported a position in NRIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.84M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Velan Capital Investment Management held 16,000 shares of Nurix Therapeutics worth $248K as of Q1 2026.
  • Velan Capital Investment Management left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up 0.16% of Velan Capital Investment Management's portfolio in Q1 2026, its #33 holding.
  • Velan Capital Investment Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Velan Capital Investment Management's Nurix Therapeutics position peaked at $1.84M in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.